Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report)'s share price shot up 5.2% on Thursday . The stock traded as high as C$2.25 and last traded at C$2.22. 25,264 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 105,689 shares. The stock had previously closed at C$2.11.
Medicenna Therapeutics Trading Up 5.2 %
The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.65 and a current ratio of 2.51. The company has a 50 day moving average of C$2.16 and a two-hundred day moving average of C$2.15. The stock has a market cap of C$169.67 million, a PE ratio of -5.84 and a beta of 1.21.
About Medicenna Therapeutics
(
Get Free Report)
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medicenna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicenna Therapeutics wasn't on the list.
While Medicenna Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
